MET Stats & Data
CCN(C)CCC1=CNC2=CC=CC=C21MYEGVMLMDWYPOA-UHFFFAOYSA-NReceptor Profile
Receptor Actions
History & Culture
MET was first documented in scientific literature in 1981, appearing in Michael Valentine Smith's book "Psychedelic Chemistry." The compound subsequently received a brief entry in Alexander Shulgin's 1997 publication "TiHKAL" (Tryptamines I Have Known and Loved), though it did not receive extensive characterization in that work. The substance emerged on the European drug market as a novel designer drug in 2014, marking its first appearance in recreational contexts. By mid-2016, MET had become available through online research chemical vendors, where it continues to be distributed for recreational and entheogenic purposes.
The toxicity and long-term health effects of recreational MET use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because MET is a research chemical with very little history of human usage. Anecdotal evidence from people within the community who have tried MET suggest that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption. It is strongly recommended that one use harm reduction practices when using this substance.
Carcinogenicity
No indication of carcinogenicity to humans (not listed by IARC).
Liver injury risk
No documented concern
Effect Profile
Curated + 14 ReportsStrong visuals with mild headspace and body load
Duration Timeline
BluelightTolerance & Pharmacokinetics
drugs.wikiTolerance Decay
Acute tolerance: develops within a single session — the reset numbers above apply after sustained heavy use, not after one binge. Within-session tachyphylaxis usually resets largely overnight.
Cross-Tolerances
Experience Report Analysis
ErowidDemographics
Gender Distribution
Age Distribution
Reports Over Time
Effect Analysis
ErowidEffects aggregated from 14 experience reports (14 Erowid)
Effect Sentiment Distribution
Confidence Distribution
Positive Effects 7
Adverse Effects 1
Real-World Dose Distribution
62K DosesFrom 21 individual dose entries
Smoked (n=15)
Form / Preparation
Most common forms and preparations reported
Redose Patterns
Redosing behavior across 11 reports
Legal Status
| Country | Status | Notes |
|---|---|---|
| Germany | NpSG (Controlled) | Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) as of July 18, 2019. Production, import with intent to distribute, administration to others, and trading are punishable offenses. Possession is prohibited but not subject to criminal penalty. |
| Japan | Controlled | Designated as a controlled substance as of March 20, 2023. |
| New Zealand | Class C | Controlled as a structural analogue of DMT under New Zealand's drug legislation. |
| Switzerland | Uncontrolled | Not listed under Buchstabe A, B, C, or D of Swiss controlled substances legislation. May be considered legal for possession. |
| United Kingdom | Class A | Controlled under the Misuse of Drugs Act 1971 via a generic clause added in 1977 that covers tryptamine derivatives modified by alkyl substitution at the nitrogen atom of the side chain. |
| United States | Unscheduled (Analogue Act may apply) | MET is not specifically scheduled under the Controlled Substances Act. However, it may be considered a controlled substance analogue of DMT or DET, meaning sales for human consumption or possession with intent to ingest could potentially be prosecuted under the Federal Analogue Act. |